98%
921
2 minutes
20
Purpose: This study introduces and evaluates a hybrid dynamic conformal arc-volumetric modulated arc therapy (hDCA-VMAT) technique for lung stereotactic body radiotherapy (SBRT). The goal is to combine the planning efficiency of VMAT with the delivery robustness of dynamic conformal arc (DCA) techniques, particularly for low-density lung targets where motion and dose calculation uncertainties pose challenges.
Methods: Twenty-four previously treated lung SBRT cases were retrospectively replanned using hDCA-VMAT, conventional VMAT, and aperture controlled VMAT (VMAT_AC). hDCA-VMAT plans were initiated with a manually created DCA plan, followed by limited inverse optimization with constrained aperture modulation. Plans were created in Eclipse v16.1 and calculated using the AcurosXB algorithm. Dosimetric plan quality, beam complexity, and delivery efficiency were assessed. Complexity was quantified using aperture-based metrics (e.g., average leaf pair opening, beam area, modulation index). Pretreatment delivery accuracy was evaluated via EPID-based gamma analysis at 3%/1, 2%/1, and 1%/1 mm Gamma criteria.
Results: All techniques produced clinically acceptable plans. Target coverage and conformity indices were comparable, but hDCA-VMAT plans demonstrated reduced mid-dose spread and significantly lower modulation. hDCA-VMAT achieved the lowest modulation factor (2.1 ± 0.52) and shortest beam on time (1.74 ± 0.46 min), a 27%-30% reduction compared to VMAT and VMAT_AC. Beam complexity metrics confirmed larger, more circular apertures for hDCA-VMAT. Gamma pass rates were significantly higher for hDCA-VMAT across all criteria, particularly under stringent 1%/1 mm criteria.
Conclusion: The hDCA-VMAT technique offers a practical, streamlined approach for lung SBRT planning that reduces modulation while maintaining high plan quality. By initiating with a DCA plan and applying limited optimization only when necessary, hDCA-VMAT minimizes planning complexity and improves delivery efficiency. These benefits are especially relevant for treating low-density lung tumors, where robustness to motion and delivery accuracy are critical.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/acm2.70217 | DOI Listing |
Cancer Pathog Ther
September 2025
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27708, United States.
Background: Stereotactic body radiotherapy (SBRT) is an effective treatment for early-stage non-small cell lung cancer. However, patient breathing can affect treatment accuracy. Therefore, this study aimed to develop a bi-polar (BP) gated motion management strategy for SBRT and evaluate its feasibility geometrically and dosimetrically.
View Article and Find Full Text PDFRadiat Oncol
September 2025
Department of Breast Sarcoma and Endocrine Tumors, Karolinska University Hospital, Stockholm, Sweden.
Background: Stereotactic Body Radiotherapy (SBRT) has been proven to be a safe and effective alternative to surgery in patients with metastatic primary sarcoma. However, data describing tumor response in relation to the given radiotherapy dose is lacking. Therefore, this study aims at analyzing efficacy and dose-response relationship in a retrospective cohort.
View Article and Find Full Text PDFOncol Lett
November 2025
Department of Radiation Oncology, University Hospital Halle (Saale), D-06120 Halle (Saale), Germany.
Stereotactic body radiation therapy (SBRT) is widely used to treat inoperable non-small cell lung cancer (NSCLC). The present study analyzed the long-term (10-year) survival outcomes of patients with NSCLC treated with SBRT in a real-world setting. Patients with NSCLC treated with SBRT between 2009 and 2013 were retrospectively identified from institutional databases at the Department of Radiation Oncology, University Hospital Halle (Saale) [Halle (Saale), Germany].
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
September 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Electronic address:
Purpose / Introduction: The BLINDED FOR REVIEW trial investigated the maximum tolerated dose for ultracentral lung tumors treated with stereotactic body radiotherapy (SBRT). Here we report a spatial and dosimetric secondary analysis of the treatment plans and assess relationships between doses to targets, organs-at-risk (OARs) and clinical outcomes.
Material And Methods: Five institutions enrolled patients with ultracentral lung cancer, cT1-3N0M0, and all received 60 Gy in 8 fractions.
Ann Thorac Surg
September 2025
Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Saint Louis, MO.
Background: Outcomes after multi-modality curative-intent treatment for patients with synchronous primary early-stage-I non-small cell lung cancer (SPELC) are inadequately understood.
Methods: We performed a retrospective study using the Veterans Health Administration database of patients diagnosed with two stage I SPELC who received treatment with either stereotactic body radiotherapy (SBRT) and/or surgery from 2006-2024. We evaluated utilization of SBRT and surgery as well factors associated with overall survival (OS) and disease-free survival (DFS) via Cox proportional hazard models.